Stoke Therapeuticsの空売り状況は、投資家がStoke Therapeuticsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Stoke Therapeutics (NASDAQ:STOK) 株価情報, 空売り情報

Stoke Therapeutics

Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.

Stoke Therapeutics Inc

Barclays analyst Seth Sigman maintains Beyond (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) with a Equal-Weight and lowers the price target from $8 to $7.

News

Price Target

Analyst Ratings

BYON

Barclays Maintains Equal-Weight on Beyond, Lowers Price Target to $7

Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) owned search giant Google is the latest tech company to donate to Donald Trump's inauguration fund ahead of the highly anticipated<a href="https://www.benzinga.com/25/01/42801809/apple-ceo-tim-cook-reportedly-donates-1-million-to-trump-inauguration-joins-ranks-of-mark-zuckerberg-jeff-bezos-and-sam-altman"> Jan. 20 event.</a>
What Happened: Google announced a $1 million donation to Trump's inauguration,<a href="https://www.benzinga.com/general/politics/24/07/39826475/trumps-new-running-mate-j-d-vance-wants-to-break-up-google-could-2024-election-be-bad-for-big-te"> joining the ranks</a> of Meta Platforms, Amazon.com, Ford Motor Company and more.
Several tech billionaires including Apple CEO Tim Cook and OpenAI CEO Sam Altman have also announced $1 million donations on their own and not directly from their associated companies.
The donation by Google made on Monday was confirmed by <a href="https://www.politico.com/live-updates/2025/01/09/congress/google-donation-donald-trump-inauguration-00197233">Politico </a>on Thursday and comes as Alphabet CEO Sundar Pichai was among the tech moguls who met with Trump at Mar-A-Lago since his 2024 presidential election win.
"Google is pleased to support the 2025 inauguration, with a livestream on YouTube and a direct link on our homepage. We're also donating to the inaugural committee," Google's global head of government affairs and public policy Karen Bhatia told Politico.
Google previously donated $285,000 to the 2016 and 2020 inaugurations, a spokesperson told Politico. Google also previously promoted the inauguration on its homepage and YouTube.
Read Also: <a href="https://www.benzinga.com/24/12/42660866/trump-gets-ford-vehicles-1m-for-inauguration-will-musk-respond-or-could-he-ride-in-rival-vehicle">Trump Gets Ford Vehicles, $1M For Inauguration &#8211; Will Musk Respond Or Could He Ride In Rival Vehicle?</a>
Why It's Important: The donation from Google comes as the company has been targeted by the Department of Justice for <a href="https://www.benzinga.com/tech/24/11/42140450/doj-targets-google-chrome-poll-shows-64-oppose-alphabet-breakup-youtube-seen-as-top-prize">alleged monopolistic behavior </a>and could be forced to break up and spinoff assets like the Chrome browser.
While there's no certainty that a donation or a visit to Mar-A-Lago will sway the new administration or prevent such outcomes, changes to the DOJ&#8217;s leadership could potentially shift the company&#8217;s legal challenges.
Incoming Vice President J.D. Vance also previously said he <a href="https://www.benzinga.com/general/politics/24/07/39826475/trumps-new-running-mate-j-d-vance-wants-to-break-up-google-could-2024-election-be-bad-for-big-te">wants to break up </a>Google, which could make the company a target of the new administration.
Senator Ted Cruz (R-Texas) recently told Politico that Republicans would target Google's content moderation policies on the search engine and on YouTube.
GOOG Price Action: Alphabet stock closed at $195.39 Wednesday versus a 52-week trading range of $131.55 to $202.88. Alphabet stock is up 37% over the last year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/management/25/01/42880549/nvidia-ceo-jensen-huang-wants-to-congratulate-trump-at-mar-a-lago-but-hasnt-been-invited-yet">Nvidia CEO Jensen Huang Wants To Congratulate Trump At Mar-A-Lago, But Hasn&#8217;t Been Invited Yet</a></li>
</ul>
Photo: Shutterstock

Politics

Tech

GOOG

GOOGL

Google Donates $1 Million To Trump Inauguration, Plans YouTube Livestream: 'Pleased To Support'

RBC Capital analyst Daniel Perlin reiterates Flywire (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYW#NASDAQ">FLYW</a>) with a Outperform and maintains $25 price target.

Reiteration

FLYW

RBC Capital Reiterates Outperform on Flywire, Maintains $25 Price Target

Barclays analyst Seth Sigman maintains Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) with a Equal-Weight and lowers the price target from $95 to $89.

Barclays Maintains Equal-Weight on Best Buy Co, Lowers Price Target to $89

RBC Capital analyst Brian Abrahams reiterates Contineum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNM#NASDAQ">CTNM</a>) with a Outperform and maintains $31 price target.

CTNM

RBC Capital Reiterates Outperform on Contineum Therapeutics, Maintains $31 Price Target

Barclays analyst Matthew McClintock maintains AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) with a Overweight and raises the price target from $3024 to $3585.

Barclays Maintains Overweight on AutoZone, Raises Price Target to $3585

Barclays analyst Seth Sigman maintains Advance Auto Parts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) with a Equal-Weight and lowers the price target from $66 to $54.

Barclays Maintains Equal-Weight on Advance Auto Parts, Lowers Price Target to $54

RBC Capital analyst Steven Shemesh reiterates Albertsons Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) with a Outperform and maintains $22 price target.

RBC Capital Reiterates Outperform on Albertsons Companies, Maintains $22 Price Target

RBC Capital analyst Sam Crittenden reiterates Capstone Copper (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CS#TSX">CS</a>) with a Outperform and maintains C$12 price target.

TSX:CS

RBC Capital Reiterates Outperform on Capstone Copper, Maintains C$12 Price Target

Unum Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNM#NYSE">UNM</a>) has outperformed the market over the past 5 years by 7.91% on an annualized basis producing an average annual return of 20.39%. Currently, Unum Gr has a market capitalization of $13.32 billion. 
Buying $1000 In UNM: If an investor had bought $1000 of UNM stock 5 years ago, it would be worth $2,512.92 today based on a price of $72.95 for UNM at the time of writing.
<h3>Unum Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736435709_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In Unum Gr 5 Years Ago Would Be Worth This Much Today

On Thursday, Nokia Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>) disclosed that Openreach has selected its One Network Platform to build an open-<a target="_blank" href="https://www.globenewswire.com/news-release/2025/01/09/3006821/0/en/Nokia-and-Openreach-introduce-intent-based-networking-to-build-an-open-access-network-accelerating-UK-fiber-broadband-rollout.html" rel="noreferrer noopener">access </a>fiber network across the U.K.
Nokia&#8217;s solution is projected to enable Openreach to build a large-scale, multi-service network with lower power and space requirements. The architecture supports various deployment models, ensuring providers can seamlessly connect users to Openreach&#8217;s fiber network.
Notably, Openreach&#8217;s broadband network connects users to around 300 providers, offering high-speed fiber services in cities, towns, villages, and remote areas across the U.K.
Nokia&#8217;s One Network Platform helps meet the growing demand by offering flexibility and scale, while reducing the number of exchange buildings needed.
Built using Nokia&#8217;s One Network Platform, the network will enable Openreach to achieve its goal of connecting 25 million premises by the close of 2026, addressing the growing demand for high-speed broadband.
Using Nokia&#8217;s Altiplano and NSP network controllers, Openreach can automate fiber connectivity and simplify operations with a unified service interface and reduces OSS complexity by 85%, while providing real-time telemetry for better network performance insights.
Last week, Nokia, along with Intuitive Machines, Inc., successfully integrated the Lunar Surface Communication System into <a target="_blank" href="https://www.benzinga.com/25/01/42856421/from-earth-to-the-moon-intuitive-machines-and-nokia-launch-4glte-network" rel="noreferrer noopener">the&nbsp;IM-2 mission lander, Athena</a>.
Investors can gain exposure to NOK stock via&nbsp;iShares U.S. Digital Infrastructure and Real Estate ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDGT#NYSE">IDGT</a>) and&nbsp;First Trust Indxx NextG ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTG#NASDAQ">NXTG</a>).
Price Action: NOK shares closed higher by 0.65% at $4.66 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/24/12/42535215/nokia-supercharges-indias-broadband-with-ishan-tech-taps-zscaler-to-upgrade-cloud-protection" target="_blank" rel="noreferrer noopener">Nokia Supercharges India&#8217;s Broadband with Ishan Tech; Taps Zscaler To Upgrade Cloud Protection</a></li>
</ul>

Equities

iShares U.S. Digital Infrastructure and Real Estate ETF

IDGT

NXTG

Openreach Taps Nokia For UK Fiber Expansion: Details

RBC Capital analyst Darko Mihelic upgrades Canadian Imperial Bank (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CM#TSX">CM</a>) from Sector Perform to Outperform and raises the price target from C$97 to C$103.

Upgrades

TSX:CM

RBC Capital Upgrades Canadian Imperial Bank to Outperform, Raises Price Target to C$103

RBC Capital analyst Darko Mihelic upgrades Canadian Imperial Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CM#NYSE">CM</a>) from Sector Perform to Outperform and raises the price target from $97 to $103.

RBC Capital Upgrades Canadian Imperial Bank to Outperform, Raises Price Target to $103

RBC Capital analyst Darko Mihelic upgrades Bank of Montreal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMO#NYSE">BMO</a>) from Sector Perform to Outperform and raises the price target from $133 to $161.

RBC Capital Upgrades Bank of Montreal to Outperform, Raises Price Target to $161

RBC Capital analyst Darko Mihelic upgrades Bank of Montreal (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BMO#TSX">BMO</a>) from Sector Perform to Outperform and raises the price target from C$133 to C$161.

TSX:BMO

RBC Capital Upgrades Bank of Montreal to Outperform, Raises Price Target to C$161

General

Real Estate

NMRK

Newmark Group Has Arranged The $360M Sale Of Two Park Avenue In Manhattan. The Transaction Is The Largest Advisor-led, All-office Property Sale In New York City In 2024

ARCH

CEIX

Arch Resources, CONSOL Energy Stockholders Vote To Approve All Proposals In Relation To Pending Combination

Treatment with ECUR-506 resulted in a complete clinical response from three months post exposure to the end of study (six months post exposure)
- ECUR-506 was generally well tolerated with no significant clinical safety concerns
- Insertion of a functional OTC gene through ARCUS in vivo gene editing may provide lasting clinical benefit for children with OTC deficiency who are in dire need of effective treatments

Biotech

Health Care

DTIL

Precision Biosciences' Partner iECURE Has Reported Clinical Efficacy And Safety Data In The First Patient Dosed With ECUR-506 In The Phase 1/2 OTC-HOPE Study

Revealing a significant insider sell on January 8, Randall K Fields, Chief Executive Officer at ReposiTrak (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRAK#NYSE">TRAK</a>), as per the latest SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000050471/000141588925001112//Archives/edgar/data/50471/000141588925001112/0001415889-25-001112-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday showed that Fields sold 7,500 shares of ReposiTrak. The total transaction amounted to $162,059. 
During Thursday's morning session, ReposiTrak shares up by 0.09%, currently priced at $21.22.
<h3>Get to Know ReposiTrak Better</h3>
ReposiTrak Inc is a software as a service provider with extensive capabilities that gives their customers an easy, cost-efficient way to expand their services to their benefit. The company and its subsidiaries develop, market, and support proprietary software products. These products assist the management of business operations, which helps clients to make more informed decisions. The company also provides a cloud-based solution to remain in compliance with business records and regulatory requirements. The firm's services comprise implementation, business optimization, outsourcing, technical services, education, and application hosting.
<h3>A Deep Dive into ReposiTrak's Financials</h3>
Positive Revenue Trend: Examining ReposiTrak's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 7.53% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 84.21%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): ReposiTrak's EPS reflects a decline, falling below the industry average with a current EPS of 0.09.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
Financial Valuation Breakdown:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 70.73 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 19.35 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): ReposiTrak's EV/EBITDA ratio stands at 45.73, surpassing industry benchmarks. This places the company in a position with a higher-than-average market valuation.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Important Transaction Codes</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000050471">Check Out The Full List Of ReposiTrak's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

TRAK

Insider Unloading: Randall K Fields Sells $162K Worth Of ReposiTrak Shares

In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive industry comparison, evaluating UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) against its key competitors in the Health Care Providers &amp; Services industry. By analyzing important financial metrics, market position, and growth prospects, we aim to provide valuable insights for investors and shed light on company's performance within the industry.
<h3>UnitedHealth Group Background</h3>
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the us as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>UnitedHealth Group Inc</td>
<td>34.10</td>
<td>5.11</td>
<td>1.25</td>
<td>6.59%</td>
<td>$9.73</td>
<td>$21.39</td>
<td>8.55%</td>
</tr>
<tr>
<td>Molina Healthcare Inc</td>
<td>15.21</td>
<td>3.59</td>
<td>0.44</td>
<td>6.78%</td>
<td>$0.51</td>
<td>$1.19</td>
<td>20.96%</td>
</tr>
<tr>
<td>Progyny Inc</td>
<td>30.42</td>
<td>3.57</td>
<td>1.56</td>
<td>2.34%</td>
<td>$0.01</td>
<td>$0.06</td>
<td>2.04%</td>
</tr>
<tr>
<td>Average</td>
<td>22.82</td>
<td>3.58</td>
<td>1.0</td>
<td>4.56%</td>
<td>$0.26</td>
<td>$0.62</td>
<td>11.5%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>By conducting an in-depth analysis of UnitedHealth Group, we can identify the following trends: 
<ul>
<li>
The Price to Earnings ratio of 34.1 for this company is 1.49x above the industry average, indicating a premium valuation associated with the stock.
</li>
<li>
The elevated Price to Book ratio of 5.11 relative to the industry average by 1.43x suggests company might be overvalued based on its book value.
</li>
<li>
With a relatively high Price to Sales ratio of 1.25, which is 1.25x the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
The company has a higher Return on Equity (ROE) of 6.59%, which is 2.03% above the industry average. This suggests efficient use of equity to generate profits and demonstrates profitability and growth potential.
</li>
<li>
The company exhibits higher Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $9.73 Billion, which is 37.42x above the industry average, implying stronger profitability and robust cash flow generation.
</li>
<li>
With higher gross profit of $21.39 Billion, which indicates 34.5x above the industry average, the company demonstrates stronger profitability and higher earnings from its core operations.
</li>
<li>
The company is witnessing a substantial decline in revenue growth, with a rate of 8.55% compared to the industry average of 11.5%, which indicates a challenging sales environment.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736434858_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio provides insights into the proportion of debt a company has in relation to its equity and asset value.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
In light of the Debt-to-Equity ratio, a comparison between UnitedHealth Group and its top 4 peers reveals the following information:
<ul>
<li>
Among its top 4 peers, UnitedHealth Group has a higher debt-to-equity ratio of 0.83.
</li>
<li>
This suggests a greater reliance on debt financing, which can expose the company to increased financial risk and potential volatility.
</li>
</ul>
<h3>Key Takeaways</h3>
For UnitedHealth Group, the PE, PB, and PS ratios are all high compared to its peers in the Health Care Providers &amp; Services industry, indicating potentially overvalued stock. On the other hand, the high ROE, EBITDA, and gross profit suggest strong profitability and operational efficiency. However, the low revenue growth rate may raise concerns about the company's future performance relative to its industry competitors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Markets

Evaluating UnitedHealth Group Against Peers In Health Care Providers &amp; Services Industry

Tracking Baker Brothers Portfolio - Q3 2024 Update

Chardan initiated coverage of Stoke Therapeutics (STOK) with a Buy rating and $24 price target The firm cites the potential of the company's lead a...

Stoke Therapeutics initiated with a Buy at Chardan

GeneDx ($WGS) is among the best performing small cap stocks for 2024, posting over 2600% gain. The company analyzes the complete DNA of a person, a...

GeneDx (WGS), An Emerging Powerhouse in Genomics Sees Explosive Growth

Stoke Therapeutics (STOK) announced alignment with global regulatory agencies on the design of the company's Phase 3 EMPEROR study of zorevunersen ...

Stoke Therapeutics finalizes EMPEROR study program with regulatory agencies

An announcement from Stoke Therapeutics ( ($STOK) ) is now available. Stoke Therapeutics has secured alignment with global regulatory agencies for ...

Stoke Therapeutics Gains Regulatory Alignment for Phase 3 Study

Stoke Therapeutics to initiate late-stage study for the treatment of Dravet syndrome

Analyst Joseph Stringer from Needham maintained a Buy rating on Stoke Therapeutics (STOK – Research Report) and keeping the price target at $22.00....

Buy Rating on Stoke Therapeutics Driven by Promising Phase 3 Trial and Financial Stability

Chardan keeps a Buy rating and $24 price target on Stoke Therapeutics (STOK) after the company provided a "long-awaited" update for its Phase 3 stu...

Stoke Therapeutics negative reaction after STK-001 update overdone, says Chardan

Stoke Therapeutics (STOK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew Fein from ...

Stoke Therapeutics' Promising Potential: Buy Rating Backed by Strong Phase 3 Trial Design and Positive Early Results

Leerink Partners analyst Marc Goodman has maintained their bullish stance on STOK stock, giving a Buy rating yesterday. Marc Goodman's rating is ba...

Positive Outlook on Stoke Therapeutics: Strategic Alignment and Promising Data Reinforce Long-Term Growth Potential

ABCL

ACAD

ALGS

ALKS

ARGNF

ARGX

AVTE

BCYC

BEIGF

BGNE

BIIB

BMEA

CERS

DNLI

EWTX

GLUE

HOOK

IGMS

IMCR

IMTX

INCY

INSM

KALA

KNSA

KYMR

MDGL

NRIX

PRAX

RARE

REPL

RVMD

RYTM

SGMT

SMMT

STOK

TCRX

TRDA

TSVT

VTVT

Press Releases

Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer

Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting

Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome

Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Comments

Stoke Therapeutics

空売り

Stoke Therapeutics (NASDAQ:STOK) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル